Alexander Honkala
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alexander Honkala has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Bryan Ronain Smith
Department of Biomedical Engineering, Michigan State University, East Lansing, USA
3 shared publications - Sanjay V. Malhotra
Center for Experimental Therapeutics, Oregon Health & Science University, Portland, OR 97239, USA
2 shared publications - Adam de la Zerda
Department of Structural Biology, Stanford University School of Medicine, Stanford University, Stanford, USA
1 shared publication - Chia-Feng Tsai
Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA, USA
1 shared publication Dhanir Tailor
Department of Radiation Oncology, School of Medicine, Stanford University, Stanford, CA, United States
1 shared publication- Dhanir Tailor
Center for Experimental Therapeutics, Oregon Health and Science University, Portland, OR 97239, USA
1 shared publication
Latest Publications
- Open Access
Python Encoders for Archetypal Convex Hulls (PEACH): PyTorch-Based Archetypal Analysis
Samples of closely related cells often contain substantial cell state heterogeneity, which traditional clustering-based analyses struggle to deconvolve. Archetype analysis is an alternative analysis approach that identifies a minimal convex hull enclosing all data points in a dimensionally-reduced space, such as PCA space. The points of this convex manifold, or hull, each represent theoretical extremal states specialized in a subset of functions that are mutually exclusive to the extremal states found at each other vertex. The transition between two points represents a Pareto front of tradeoffs between potential cell states. Cell distances from each archetype and direction between archetypes then carry interpretable biological information revealing features of resource tradeoffs in cell state regulation. The archetypal points themselves are theoretical pure extremal states rarely accessed by real cells, which instead display a combination of archetype weights/mixture coefficients representing a mixture of specializations. By characterizing the relationships between gene expression and archetype distance, archetypal analysis can identify the phenotypic features of theoretically pure specialist states, the phenotypic tradeoffs of real cells, and the boundaries of accessible cell states in the analyzed sample. Here we present Python Encoders for Archetypal Convex Hulls (PEACH), a new PyTorch-based archetype analysis package compatible with the scVerse ecosystem that recapitulates and extends features available in previous archetype analysis packages. This includes a hyperparameter search function to identify the best $k$ archetypes that fit an input dataset. PEACH uses a deliberately constrained autoencoder architecture to directly learn an archetypal latent space, replacing previous alternating least squares methods with a highly performant, GPU-accelerated archetype analysis method that is scalable to modern scRNAseq datasets of hundreds of thousands of cells. Crucially, PEACH includes automated hyperparameter search with cross-validation to identify optimal archetype and initialization configurations, enabling users to implement archetype analysis without extensive manual hyperparameter optimization and testing.Open AccessPython Encoders for Archetypal Convex Hulls (PEACH): PyTorch-Based Archetypal Analysis
Samples of closely related cells often contain substantial cell state heterogeneity, which traditional clustering-based analyses struggle to deconvolve. Archetype analysis is an alternative analysis approach that identifies a minimal convex hull enclosing all data points in a dimensionally-reduced space, such as PCA space. The points of this convex manifold, or hull, each represent theoretical extremal states specialized in a subset of functions that are mutually exclusive to the extremal states found at each other vertex. The transition between two points represents a Pareto front of tradeoffs between potential cell states. Cell distances from each archetype and direction between archetypes then carry interpretable biological information revealing features of resource tradeoffs in cell state regulation. The archetypal points themselves are theoretical pure extremal states rarely accessed by real cells, which instead display a combination of archetype weights/mixture coefficients representing a mixture of specializations. By characterizing the relationships between gene expression and archetype distance, archetypal analysis can identify the phenotypic features of theoretically pure specialist states, the phenotypic tradeoffs of real cells, and the boundaries of accessible cell states in the analyzed sample. Here we present Python Encoders for Archetypal Convex Hulls (PEACH), a new PyTorch-based archetype analysis package compatible with the scVerse ecosystem that recapitulates and extends features available in previous archetype analysis packages. This includes a hyperparameter search function to identify the best $k$ archetypes that fit an input dataset. PEACH uses a deliberately constrained autoencoder architecture to directly learn an archetypal latent space, replacing previous alternating least squares methods with a highly performant, GPU-accelerated archetype analysis method that is scalable to modern scRNAseq datasets of hundreds of thousands of cells. Crucially, PEACH includes automated hyperparameter search with cross-validation to identify optimal archetype and initialization configurations, enabling users to implement archetype analysis without extensive manual hyperparameter optimization and testing. - Open Access
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 2645
Abstract 2645: Targeting mRNA processing pathways in ovarian cancer with a small molecule inhibitor
MRNA processing related pathways, including spliceosome and ribosome are over-expressed and unregulated in cancer cells. To investigate the mRNA processing pathways in patient samples, we performed a comprehensive, tandem mass tag (TMT) labeling-based proteome and phosphoproteome profiling of the normal and ovarian cancerous tissues from patients treated with different chemotherapy revealed that malignant cells have overexpression of mRNA processing pathways compared to normal cells. For this analysis, equal amount of tissues were homogenized, and tissue lysates were collected and processed for the quantitative proteomics and phosphoproteomics analysis. KEGG pathway enrichment analysis revealed that spliceosome, basal transcription factors, mRNA surveillance, ribosome and ribosome biogenesis in eukaryotes pathways are upregulated in cancer cells compared to control. On other hand, pathways associated with metabolism and fatty acid biosynthesis were downregulated in malignant cells. Moreover, kinase Enrichment Analysis shows that CDK2, ATM, ATR, and MAPK associated kinases are upregulated in cancer cells compared to normal. Based on proteome analysis of patient samples, we investigated the pharmacological inhibition of Y-box binding protein 1 (YB-1). This is an RNA binding protein and key regulator of pre-mRNA alternative splicing and processing. We recently showed that a natural product-derived small molecule (SU056) inhibits YB-1 activity. We found that SU056 binds to the YB-1 and blocks the RNA binding pocket. Proteomics results suggest that treatment with this drug strongly inhibits the spliceosome pathway. SU056 treatment arrests the ovarian cancer cells in G1 phase and inhibits the CDK2 and Cyclin E. SU056 inhibits the tumor progression and metastasis in the ID8 mice model and sensitizes the OVCAR8 NSG mice model for paclitaxel treatment. Our study provides a compelling case for YB-1 inhibition using SU056 as a potential therapy for ovarian cancer. Citation Format: Dhanir Tailor, Chia-Feng Tsai, Alexander Honkala, Wenqi Li, Tao Liu, Tanja Pejovic, Sanjay V. Malhotra. Targeting mRNA processing pathways in ovarian cancer with a small molecule inhibitor [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2645.
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 2645
Open AccessAbstract 2645: Targeting mRNA processing pathways in ovarian cancer with a small molecule inhibitor
MRNA processing related pathways, including spliceosome and ribosome are over-expressed and unregulated in cancer cells. To investigate the mRNA processing pathways in patient samples, we performed a comprehensive, tandem mass tag (TMT) labeling-based proteome and phosphoproteome profiling of the normal and ovarian cancerous tissues from patients treated with different chemotherapy revealed that malignant cells have overexpression of mRNA processing pathways compared to normal cells. For this analysis, equal amount of tissues were homogenized, and tissue lysates were collected and processed for the quantitative proteomics and phosphoproteomics analysis. KEGG pathway enrichment analysis revealed that spliceosome, basal transcription factors, mRNA surveillance, ribosome and ribosome biogenesis in eukaryotes pathways are upregulated in cancer cells compared to control. On other hand, pathways associated with metabolism and fatty acid biosynthesis were downregulated in malignant cells. Moreover, kinase Enrichment Analysis shows that CDK2, ATM, ATR, and MAPK associated kinases are upregulated in cancer cells compared to normal. Based on proteome analysis of patient samples, we investigated the pharmacological inhibition of Y-box binding protein 1 (YB-1). This is an RNA binding protein and key regulator of pre-mRNA alternative splicing and processing. We recently showed that a natural product-derived small molecule (SU056) inhibits YB-1 activity. We found that SU056 binds to the YB-1 and blocks the RNA binding pocket. Proteomics results suggest that treatment with this drug strongly inhibits the spliceosome pathway. SU056 treatment arrests the ovarian cancer cells in G1 phase and inhibits the CDK2 and Cyclin E. SU056 inhibits the tumor progression and metastasis in the ID8 mice model and sensitizes the OVCAR8 NSG mice model for paclitaxel treatment. Our study provides a compelling case for YB-1 inhibition using SU056 as a potential therapy for ovarian cancer. Citation Format: Dhanir Tailor, Chia-Feng Tsai, Alexander Honkala, Wenqi Li, Tao Liu, Tanja Pejovic, Sanjay V. Malhotra. Targeting mRNA processing pathways in ovarian cancer with a small molecule inhibitor [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2645.
- 1 March 2020
- Published by Elsevier in Trends in Cancer
- Vol. 6 (3) , 205-222
Optical Microscopy and Coherence Tomography of Cancer in Living Subjects
- 1 March 2020
- Published by Elsevier in Trends in Cancer
- Vol. 6 (3) , 205-222
Optical Microscopy and Coherence Tomography of Cancer in Living Subjects
- Open Access
- 24 January 2020
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 10, 3139
Guanylate-Binding Protein 1: An Emerging Target in Inflammation and Cancer
Guanylate-binding protein 1 (GBP1) is a large GTPase of the dynamin superfamily involved in the regulation of membrane, cytoskeleton, and cell cycle progression dynamics. In many cell types, such as endothelial cells and monocytes, GBP1 expression is strongly provoked by interferon γ (IFNγ) and acts to restrain cellular proliferation in inflammatory contexts. In immunity, GBP1 activity is crucial for the maturation of autophagosomes infected by intracellular pathogens and the cellular response to pathogen-associated molecular patterns. In chronic inflammation, GBP1 activity inhibits endothelial cell proliferation even as it protects from IFNγ-induced apoptosis. A similar inhibition of proliferation has also been found in some tumor models, such as colorectal or prostate carcinoma mouse models. However, this activity appears to be context-dependent, as in other cancers, such as oral squamous cell carcinoma and ovarian cancer, GBP1 activity appears to anchor a complex, taxane chemotherapy resistance profile where its expression levels correlate with worsened prognosis in patients. This discrepancy in GBP1 function may be resolved by GBP1's involvement in the induction of a cellular senescence phenotype, wherein anti-proliferative signals coincide with potent resistance to apoptosis and set the stage for dysregulated proliferative mechanisms present in growing cancers to hijack GBP1 as a pro- chemotherapy treatment resistance (TXR) and pro-survival factor even in the face of continued cytotoxic treatment. While the structure of GBP1 has been extensively characterized, its roles in inflammation, TXR, senescence, and other biological functions remain under-investigated, although initial findings suggest that GBP1 is a compelling target for therapeutic intervention in a variety of conditions ranging from chronic inflammatory disorders to cancer.
- 24 January 2020
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 10, 3139
Open AccessGuanylate-Binding Protein 1: An Emerging Target in Inflammation and Cancer
Guanylate-binding protein 1 (GBP1) is a large GTPase of the dynamin superfamily involved in the regulation of membrane, cytoskeleton, and cell cycle progression dynamics. In many cell types, such as endothelial cells and monocytes, GBP1 expression is strongly provoked by interferon γ (IFNγ) and acts to restrain cellular proliferation in inflammatory contexts. In immunity, GBP1 activity is crucial for the maturation of autophagosomes infected by intracellular pathogens and the cellular response to pathogen-associated molecular patterns. In chronic inflammation, GBP1 activity inhibits endothelial cell proliferation even as it protects from IFNγ-induced apoptosis. A similar inhibition of proliferation has also been found in some tumor models, such as colorectal or prostate carcinoma mouse models. However, this activity appears to be context-dependent, as in other cancers, such as oral squamous cell carcinoma and ovarian cancer, GBP1 activity appears to anchor a complex, taxane chemotherapy resistance profile where its expression levels correlate with worsened prognosis in patients. This discrepancy in GBP1 function may be resolved by GBP1's involvement in the induction of a cellular senescence phenotype, wherein anti-proliferative signals coincide with potent resistance to apoptosis and set the stage for dysregulated proliferative mechanisms present in growing cancers to hijack GBP1 as a pro- chemotherapy treatment resistance (TXR) and pro-survival factor even in the face of continued cytotoxic treatment. While the structure of GBP1 has been extensively characterized, its roles in inflammation, TXR, senescence, and other biological functions remain under-investigated, although initial findings suggest that GBP1 is a compelling target for therapeutic intervention in a variety of conditions ranging from chronic inflammatory disorders to cancer.
- 3 January 2020
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 12 (4) , 2752-2763
Nanoparticles decorated with granulocyte-colony stimulating factor for targeting myeloid cells
Dysregulated myeloid cell activity underlies a variety of pathologies, including immunosuppression in malignant cancers. Current treatments to alter myeloid cell behavior also alter other immune cell subpopulations and nonimmune cell types with deleterious side effects. Therefore, improved selectivity of myeloid treatment is an urgent need. To meet this need, we demonstrate a novel, targeted nanoparticle system that achieves superior myeloid selectivity both in vitro and in vivo. This system comprises: (1) granulocyte-colony stimulating factor (G-CSF) as a targeting ligand to promote accumulation in myeloid cells, including immunosuppressive myeloid-derived suppressor cells (MDSCs); (2) albumin nanoparticles 100–120 nm in diameter that maintain morphology and drug payload in simulated physiological conditions; and (3) a fluorophore that enables nanoparticle tracking and models a therapeutic molecule. Here, we show that this strategy achieves high myeloid uptake in mixed primary immune cells and that nanoparticles successfully infiltrate the 4T1 triple-negative breast tumor murine microenvironment, where they preferentially accumulate in myeloid cells in a mouse model. Further development will realize diagnostic myeloid cell tracking applications and therapeutic delivery of myeloid-reprogramming drugs.
- 3 January 2020
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 12 (4) , 2752-2763
Nanoparticles decorated with granulocyte-colony stimulating factor for targeting myeloid cells
Dysregulated myeloid cell activity underlies a variety of pathologies, including immunosuppression in malignant cancers. Current treatments to alter myeloid cell behavior also alter other immune cell subpopulations and nonimmune cell types with deleterious side effects. Therefore, improved selectivity of myeloid treatment is an urgent need. To meet this need, we demonstrate a novel, targeted nanoparticle system that achieves superior myeloid selectivity both in vitro and in vivo. This system comprises: (1) granulocyte-colony stimulating factor (G-CSF) as a targeting ligand to promote accumulation in myeloid cells, including immunosuppressive myeloid-derived suppressor cells (MDSCs); (2) albumin nanoparticles 100–120 nm in diameter that maintain morphology and drug payload in simulated physiological conditions; and (3) a fluorophore that enables nanoparticle tracking and models a therapeutic molecule. Here, we show that this strategy achieves high myeloid uptake in mixed primary immune cells and that nanoparticles successfully infiltrate the 4T1 triple-negative breast tumor murine microenvironment, where they preferentially accumulate in myeloid cells in a mouse model. Further development will realize diagnostic myeloid cell tracking applications and therapeutic delivery of myeloid-reprogramming drugs.
- 1 November 2017
- Published by Elsevier in Drug Resistance Updates
- Vol. 33-35, 23-35
Cancer Immunotherapy Getting Brainy: Visualizing the Distinctive CNS Metastatic Niche to Illuminate Therapeutic Resistance
- 1 November 2017
- Published by Elsevier in Drug Resistance Updates
- Vol. 33-35, 23-35
Cancer Immunotherapy Getting Brainy: Visualizing the Distinctive CNS Metastatic Niche to Illuminate Therapeutic Resistance
- Open Access
- 1 January 2011
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 79 (1) , 185-191
Probiotic Lactobacillus reuteri Ameliorates Disease Due to Enterohemorrhagic Escherichia coli in Germfree Mice
Strains of enterohemorrhagic Escherichia coli (EHEC) are a group of Shiga toxin-producing food-borne pathogens that cause severe hemorrhagic colitis and can lead to hemolytic-uremic syndrome (HUS), a life-threatening condition that principally affects children and for which there is no effective treatment. We used a germfree mouse model of renal and enteric disease due to EHEC to determine if probiotic Lactobacillus reuteri ATCC PTA 6475 is effective in suppressing disease symptoms caused by EHEC. When germfree Swiss Webster mice are monocolonized with EHEC, they develop disease characterized by weight loss, cecal luminal fluid accumulation, and renal tubular necrosis. When L. reuteri was administered 1 day prior to EHEC challenge and every other day thereafter, EHEC colonization was suppressed and mice were significantly protected from the manifestations of disease. Protection from disease did not require the induction of the antimicrobial compound reuterin in L. reuteri prior to treatment. The twice-daily administration of L. reuteri appeared more effective than every-other-day administration. These data indicated that L. reuteri partially protects mice from disease manifestations of EHEC.
- 1 January 2011
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 79 (1) , 185-191
Open AccessProbiotic Lactobacillus reuteri Ameliorates Disease Due to Enterohemorrhagic Escherichia coli in Germfree Mice
Strains of enterohemorrhagic Escherichia coli (EHEC) are a group of Shiga toxin-producing food-borne pathogens that cause severe hemorrhagic colitis and can lead to hemolytic-uremic syndrome (HUS), a life-threatening condition that principally affects children and for which there is no effective treatment. We used a germfree mouse model of renal and enteric disease due to EHEC to determine if probiotic Lactobacillus reuteri ATCC PTA 6475 is effective in suppressing disease symptoms caused by EHEC. When germfree Swiss Webster mice are monocolonized with EHEC, they develop disease characterized by weight loss, cecal luminal fluid accumulation, and renal tubular necrosis. When L. reuteri was administered 1 day prior to EHEC challenge and every other day thereafter, EHEC colonization was suppressed and mice were significantly protected from the manifestations of disease. Protection from disease did not require the induction of the antimicrobial compound reuterin in L. reuteri prior to treatment. The twice-daily administration of L. reuteri appeared more effective than every-other-day administration. These data indicated that L. reuteri partially protects mice from disease manifestations of EHEC.